Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

Most metaphors of aging suggest that after a certain point, we are over the hill and face an inevitable decline. If you eat your veggies and get in your steps, the common-sense view goes, you may be ...

With a reverse mortgage, homeowners aged 62 or older can tap a valuable asset for cash without making monthly payments. Instead, payment is due when you sell the house, stop living in the house ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

At first glance, some of the language looks familiar. A letter sent to state officials in Rhode Island by the Justice Department in June included a reminder that federal civil rights law "prohibits an ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...

Pirtobrutinib significantly improved progression-free survival in treatment-naive CLL/SLL patients, reducing disease progression risk by 80% compared to bendamustine plus rituximab. The trial ...

At a median duration of follow-up of 6.6 months, treatment with pirtobrutinib reduced the risk of progression or death by 42%. The Food and Drug Administration (FDA) has approved Jaypirca ® ...